Cargando…
Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial
BACKGROUND: Ansofaxine (LY03005) extended-release tablet is a potential triple reuptake inhibitor of serotonin, norepinephrine, and dopamine. This study assessed the efficacy, safety, and appropriate dosage of ansofaxine for the treatment of major depressive disorder (MDD). METHODS: A multicenter, r...
Autores principales: | Mi, Weifeng, Yang, Fude, Li, Huafang, Xu, Xiufeng, Li, Lehua, Tan, Qingrong, Wang, Guoqiang, Zhang, Kerang, Tian, Feng, Luo, Jiong, Xia, Jielai, Yuan, Kai, Lu, Lin, Deng, Jiahui, Tian, Jingwei, Zhang, Hongyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8929756/ https://www.ncbi.nlm.nih.gov/pubmed/34747448 http://dx.doi.org/10.1093/ijnp/pyab074 |
Ejemplares similares
-
A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder
por: Mi, Weifeng, et al.
Publicado: (2023) -
An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
por: Si, TianMei, et al.
Publicado: (2015) -
A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
por: Downing, AnnCatherine M, et al.
Publicado: (2014) -
Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome
por: Luo, Linlin, et al.
Publicado: (2016) -
A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults
por: He, Shen, et al.
Publicado: (2023)